Exelixis, Inc. (EXEL)

In the past six months, Exelixis's stock has been impacted by several key events, including surpassing analyst expectations with its quarterly earnings reports. In the first quarter of 2026, Exelixis reported non-GAAP diluted EPS of $0.87 and total revenues of $610.8 million, leading to a positive market reaction. The company authorized an additional $750 million stock repurchase plan in May 2026. The FDA accepted the NDA for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer in February 2026, with a PDUFA target action date of December 3, 2026. Over the past 52 weeks, Exelixis stock has traded between $33.76 and $49.62.

Exelixis does not operate in a significantly cyclical industry. Its business is primarily tied to drug pipelines, clinical approvals, and the ongoing demand for chronic cancer treatments, which tend to exhibit stability rather than seasonal fluctuations. Demand for its key product, Cabometyx, has remained high.

Exelixis, Inc. is an oncology-focused biotechnology company dedicated to discovering, developing, and commercializing new medicines for difficult-to-treat cancers. Its major products include Cabometyx, approved for advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer; Cometriq, another formulation of cabozantinib for progressive, metastatic medullary thyroid cancer; and Cotellic, an inhibitor of MEK approved for certain forms of advanced melanoma. The company is also advancing its product pipeline, with zanzalintinib being a lead investigational asset.

Exelixis, Inc. is headquartered in Alameda, California, U.S. The company's cabozantinib franchise has an expanding international footprint through partnerships with Ipsen for markets outside the U.S., Canada, and Japan, and with Takeda for other regions.

In the past year, Exelixis has maintained a strong market presence and robust investor confidence. The company has received positive analyst reviews, highlighting it as a strong value and growth stock. Its consistent financial performance and advancements in its pipeline contribute to a positive reputation within the biotechnology sector.

The ownership structure of Exelixis is heavily dominated by institutional investors, who collectively held approximately 85.27% of the company's stock as of July 2025. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Farallon Capital Management Llc, Renaissance Technologies Llc, Aqr Capital Management Llc, State Street Corp, Fuller & Thaler Asset Management, Inc., Lsv Asset Management, Geode Capital Management, Llc, and Invesco Ltd. As of December 30, 2025, BlackRock, Inc. held 30,201,675 shares and The Vanguard Group, Inc. held 25,490,449 shares.